GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 132 Note 7 : Non-current financial assets - Loans ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Loans to related parties - Unsecured considered good 204,60.00 - 204,60.00 - Note 8 : Non-current financial assets - Others ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Margin money / Deposit against bank guarantee 4,10.78 4,01.47 Security Deposits - Unsecured considered good 6,94.06 8,06.08 Security Deposits - Unsecured considered doubtful 2,41.34 2,41.34 Less: Allowance for doubtful deposits (2,41.34) (2,41.34) 11,04.84 12,07.55 Note 9 : Other non-current assets ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Capital advances 3,13.23 2,87.24 Less : Allowance for doubtful advances (2,83.17) (2,83.17) 30.06 4.07 Balances with Government Authorities 11,84.22 11,58.27 Sundry Deposits 31,48.18 31,23.66 Others 1,33.18 3,02.02 44,95.64 45,88.02 Note 10 : Inventories (at lower of cost or net realisable value) ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Raw materials and Packing materials (includes in-transit as on March 31, 2022: ` Nil lakhs; March 31, 2021 ` 9,06.49 lakhs) 95,27.74 88,88.47 Work-in-progress 72.86 1,06.14 Finished goods 140,55.22 116,21.99 Stock-in-trade (includes in-transit as on March 31, 2022: ` 9,30.83 lakhs; March 31, 2021 ` 17,11.20 lakhs) 272,27.35 313,38.13 Stores and spares 3,88.15 3,79.12 512,71.32 523,33.85 Note 11 : Current Investments ( ` in lakhs) As at March 31, 2022 As at March 31, 2021 Quoted Investments measured at Fair value through profit and loss Investment in Mutual Funds 365,59.23 - 365,59.23 -